Author | FD type | All BA cases | Complications (%) | Ischemic complications (%) | Hemorrhagic complications (%) | Mass effect (%) | Other (%) | Morbidity (%) | Mortality (%) | CO at FU (total FU cases, %) |
Bender et al 201818 | PED | 14 | 2 (14.3) | 2 (14.3) | 0 (0) | 0 (0) | 0 (0) | 1 (7.1) | 1 (7.1) | NA |
Dmytriw et al 201819 | PED/FRED | 16 | 3 (18,8) | 0 (0) | 2 (12.5) | 1 (6.3) | 0 (0) | 0 (0) | 1 (6.3) | 11 (14, 78.6) |
Griessenauer et al 20185 | PED | 46 | 15 (32.6) | NA | NA | NA | NA | NA | NA | 33 (46,71.7) |
Tashner et al 20176 | Surpass | 26 | NA | NA | NA | NA | NA | NA | 8 (30.8) | NA |
Lopes et al 201721 | PED | 44 | 8 (18.2) | 6 (13.6) | 1 (2.3) | 1 (2.3) | 0 (0) | 3 (6.8) | 6 (13.6) | NA |
Da Ros et al 20177 | PED/SILK/ FRED | 5 | 2 (40) | 1 (20) | 1 (20) | 0 (0) | 0 (0) | 1 (20) | 1 (20) | 5 (5, 100) |
Wakhloo et al 201522 | Surpass | 9 | 4 (44.4) | 2 (22.2) | 0 (0) | 2 (22.2) | 0 (0) | 2 (22.2) | 2 (22.2) | 4 (6, 66.6) |
Albuquerque 201523 | PED | 8 | 3 (37.5) | 1 (12.5) | 1 (12.5) | 0 (0) | 1 (12.5) | 0 (0) | 0 (0) | 6 (7, 85.7) |
Monteith et al 201424 | PED | 5 | 2 (40) | 1 (20) | 1 (20) | 0 (0) | 0 (0) | 1 (20) | 1 (20) | 1 (4, 25) |
Toma et al 201325 | PED/SILK | 8 | 5 (62.5) | 2 (25.0) | 1 (12.5) | 1 (12.5) | 1 (12.5) | 2 (25.0) | 3 (37.5) | NA |
Siddiqui et al 201226 | PED/SILK | 7 | 5 (71.4) | 3 (42.9) | 2 (28.6) | 0 (0) | 0 (0) | 1 (14.3) | 4 (57.1) | NA |
Phillips et al 201227 | PED | 21 | 6 (28.6) | 4 (19.0) | 2 (9.5) | 0 (0) | 0 (0) | 3 (14.3) | 0 (0) | NA |
Kulcsár et al 201028 | SILK | 12 | 5 (41.7) | 5 (41.7) | 0 (0) | 0 (0) | 0 (0) | 3 (25.0) | 0 (0) | 7 (12, 58.3) |
Byrne et al 201029 | SILK | 8 | 3 (37.5) | 1 (12.5) | 0 (0) | 2 (25. | 0 (0) | 1 (12.5) | 2 (25) | NA |
Total | 229 | |||||||||
Total (mean %) | 63 (31.0) | 28 (17.8) | 11 (7.0) | 7 (4.45) | 4 (2.5) | 18 (11.5) | 29 (14.3) | 67 (71.3) |
BA, basilar artery; CO, complete occlusion; FD, flow diverter; FRED, flow redirection endoluminal device; FU, follow-up; NA, data not available; PED, pipeline embolization device.